Arvee Laboratories [ARVEE] vs Grauer & Weil [GRAUWEIL] Detailed Stock Comparison

Arvee Laboratories
NSE
Loading...

Grauer & Weil
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Arvee Laboratories wins in 3 metrics, Grauer & Weil wins in 15 metrics, with 0 ties. Grauer & Weil appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Arvee Laboratories | Grauer & Weil | Better |
---|---|---|---|
P/E Ratio (TTM) | 85.55 | 26.73 | Grauer & Weil |
Price-to-Book Ratio | 6.25 | 4.48 | Grauer & Weil |
Debt-to-Equity Ratio | 3.31 | 1.26 | Grauer & Weil |
PEG Ratio | -2.35 | 37.25 | Arvee Laboratories |
EV/EBITDA | 54.04 | 20.89 | Grauer & Weil |
Profit Margin (TTM) | 3.88% | 13.35% | Grauer & Weil |
Operating Margin (TTM) | 2.84% | 18.36% | Grauer & Weil |
EBITDA Margin (TTM) | 2.84% | 18.36% | Grauer & Weil |
Return on Equity | 3.61% | 16.73% | Grauer & Weil |
Return on Assets (TTM) | 2.75% | 12.23% | Grauer & Weil |
Free Cash Flow (TTM) | $10.78M | $999.80M | Grauer & Weil |
Dividend Yield | N/A | 1.05% | N/A |
1-Year Return | -11.74% | -0.82% | Grauer & Weil |
Price-to-Sales Ratio (TTM) | 5.27 | 3.74 | Grauer & Weil |
Enterprise Value | $1.86B | $36.79B | Grauer & Weil |
EV/Revenue Ratio | 6.12 | 3.27 | Grauer & Weil |
Gross Profit Margin (TTM) | 41.17% | 41.05% | Arvee Laboratories |
Revenue per Share (TTM) | $32 | $25 | Arvee Laboratories |
Earnings per Share (Diluted) | $1.98 | $3.47 | Grauer & Weil |
Beta (Stock Volatility) | N/A | 0.28 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Arvee Laboratories vs Grauer & Weil Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Arvee Laboratories | -0.33% | 0.15% | -10.06% | 14.54% | 21.71% | -3.79% |
Grauer & Weil | 0.05% | -2.32% | -11.54% | 9.08% | 6.92% | -11.88% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Arvee Laboratories | -11.74% | 99.28% | 720.29% | 178.14% | 178.14% | 178.14% |
Grauer & Weil | -0.82% | 39.06% | 116.96% | 385.60% | 953.98% | 726.65% |
Performance & Financial Health Analysis: Arvee Laboratories vs Grauer & Weil
Metric | ARVEE | GRAUWEIL |
---|---|---|
Market Information | ||
Market Cap | ₹1.87B | ₹42.05B |
Market Cap Category | Small cap | Small cap |
10 Day Avg. Volume | 243 | 141,218 |
90 Day Avg. Volume | 893 | 163,561 |
Last Close | ₹169.39 | ₹92.75 |
52 Week Range | ₹126.54 - ₹235.79 | ₹78.00 - ₹120.00 |
% from 52W High | -28.16% | -22.71% |
All-Time High | ₹315.00 (Apr 08, 2024) | ₹204.80 (Feb 26, 2024) |
% from All-Time High | -46.23% | -54.71% |
Growth Metrics | ||
Quarterly Revenue Growth | -0.28% | -0.04% |
Quarterly Earnings Growth | -0.82% | -0.14% |
Financial Health | ||
Profit Margin (TTM) | 0.04% | 0.13% |
Operating Margin (TTM) | 0.03% | 0.18% |
Return on Equity (TTM) | 0.04% | 0.17% |
Debt to Equity (MRQ) | 3.31 | 1.26 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | ₹27.11 | ₹20.72 |
Cash per Share (MRQ) | N/A | ₹11.87 |
Operating Cash Flow (TTM) | ₹46.04M | ₹1.68B |
Levered Free Cash Flow (TTM) | ₹10.52M | ₹1.57B |
Dividends | ||
Last 12-Month Dividend Yield | N/A | 1.05% |
Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Arvee Laboratories vs Grauer & Weil
Metric | ARVEE | GRAUWEIL |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 85.55 | 26.73 |
Forward P/E | N/A | 37.25 |
PEG Ratio | -2.35 | 37.25 |
Price to Sales (TTM) | 5.27 | 3.74 |
Price to Book (MRQ) | 6.25 | 4.48 |
Market Capitalization | ||
Market Capitalization | ₹1.87B | ₹42.05B |
Enterprise Value | ₹1.86B | ₹36.79B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 6.12 | 3.27 |
Enterprise to EBITDA | 54.04 | 20.89 |
Risk & Other Metrics | ||
Beta | N/A | 0.28 |
Book Value per Share (MRQ) | ₹27.11 | ₹20.72 |
Financial Statements Comparison: Arvee Laboratories vs Grauer & Weil
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | ARVEE | GRAUWEIL |
---|---|---|
Revenue/Sales | ₹89.09M | ₹3.40B |
Cost of Goods Sold | ₹52.41M | ₹2.00B |
Gross Profit | ₹36.68M | ₹1.40B |
Research & Development | N/A | N/A |
Operating Income (EBIT) | ₹729,000 | ₹237.20M |
EBITDA | ₹5.35M | ₹417.40M |
Pre-Tax Income | ₹2.07M | ₹343.50M |
Income Tax | ₹520,000 | ₹86.10M |
Net Income (Profit) | ₹1.55M | ₹257.40M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | ARVEE | GRAUWEIL |
---|---|---|
Cash & Equivalents | ₹3.58M | ₹1.08B |
Total Current Assets | ₹240.26M | ₹9.36B |
Total Current Liabilities | ₹68.79M | ₹2.97B |
Long-Term Debt | ₹10.00M | ₹37.30M |
Total Shareholders Equity | ₹310.38M | ₹9.39B |
Retained Earnings | N/A | N/A |
Property, Plant & Equipment | ₹129.87M | ₹2.47B |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | ARVEE | GRAUWEIL |
---|---|---|
Operating Cash Flow | N/A | N/A |
Capital Expenditures | N/A | N/A |
Free Cash Flow | N/A | N/A |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | ARVEE | GRAUWEIL |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 243 | 141,218 |
Average Daily Volume (90 Day) | 893 | 163,561 |
Shares Outstanding | 11.02M | 453.41M |
Float Shares | 2.31M | 127.47M |
% Held by Insiders | N/A | 0.72% |
% Held by Institutions | N/A | 0.00% |
Dividend Analysis & Yield Comparison: Arvee Laboratories vs Grauer & Weil
Metric | ARVEE | GRAUWEIL |
---|---|---|
Last 12-Month Dividend | N/A | ₹1.00 |
Last 12-Month Dividend Yield | N/A | 1.05% |
3-Year Avg Annual Dividend | N/A | ₹0.58 |
3-Year Avg Dividend Yield | N/A | 0.45% |
3-Year Total Dividends | N/A | ₹1.73 |
Ex-Dividend Date | N/A | Aug 06, 2025 |